Recently, highly specific PSMA ligands such as 68Ga-labeled HBED-CC-PSMA or 18F-labeled DCFPyl have been developed and clinically tested, showing promising results for the detection of PCa lesions with PET/CT [16–18]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.